Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. - Test2 - elhamkhani - TriplyDB

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

http://www.wikidata.org/entity/Q34334262

about

New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers Breast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with Metformin Obesity and cancer: mechanistic insights from transdisciplinary studies Metformin and breast cancer stage at diagnosis: a population-based study Metformin in breast cancer - an evolving mystery.Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectom Metformin Is Associated with a Favorable Outcome in Diabetic Patients with Cervical Lymph Node Metastasis of Differentiated Thyroid Cancer Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis Measuring the biological effect of presurgical metformin treatment in endometrial cancer.Prognostic value of glycated hemoglobin in colorectal cancer.The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug Expression of a mutant prohibitin from the aP2 gene promoter leads to obesity-linked tumor development in insulin resistance-dependent manner.Expanding the therapeutic spectrum of metformin: from diabetes to cancer.Metformin: risk-benefit profile with a focus on cancer.Designs of preoperative biomarkers trials in oncology: a systematic review of the literature.The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).The impact of metformin use on survival in prostate cancer: a systematic review and meta-analysis.Examining the prevalence of metabolic syndrome among overweight/obese African-American breast cancer survivors vs. matched non-cancer controls.

P2860

Q26774577-6B8896D8-AB39-4394-A2C1-AE860AF12B7B Q26775580-5EA6483D-9730-4E45-A3E6-B8E662A01154 Q26786829-77A2576D-CD95-4C58-95BB-2CAADB7A2DD1 Q33611185-9101BF2D-4AAA-4940-B72C-DF9339740221 Q35780739-75E9B8D5-AC00-4480-A417-A1837F969496 Q35916210-AF700E15-BA84-45F2-B49B-5109C081D59F Q36261224-2DBC2C5C-EA2C-42C7-ADD0-42BDE2708766 Q36516580-6D8B3440-48A6-416F-9A21-29E4D18C9F51 Q36547907-2F959A17-B9E0-44E0-9C7C-E528A1CECDAE Q37483467-DEC1CE05-CC00-4533-B34D-6A9ACBF2E1BA Q37501673-2B7A2112-1311-4C67-8818-79300D1D57EB Q38294405-337977D1-0E62-478D-B0D9-90641353B06F Q38558943-07091709-6511-4288-B162-0F49B700004B Q38584636-EC923D05-1225-4B25-B250-7E1ACD64D9AB Q38586993-29068304-3CB7-4397-992D-73AAD0D088F9 Q38728567-9A959041-39F3-4B8D-A567-7F28BDFFB094 Q38792334-755EC3A1-C174-48BD-A906-7B0B124AB213 Q39031270-AA00A0D8-C135-4451-9106-204540879326 Q47116201-3E8020A0-67BD-453D-BE18-D81B517D9B54 Q53753091-4274BC44-66F8-48F4-9181-655B2F504D11

P2860

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

http://www.wikidata.org/entity/Q34334262

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Differential effects of metfor ...... randomized presurgical trial.

@ast

Differential effects of metfor ...... randomized presurgical trial.

@en

Differential effects of metfor ...... randomized presurgical trial.

@nl

type

label

Differential effects of metfor ...... randomized presurgical trial.

@ast

Differential effects of metfor ...... randomized presurgical trial.

@en

Differential effects of metfor ...... randomized presurgical trial.

@nl

prefLabel

Differential effects of metfor ...... randomized presurgical trial.

@ast

Differential effects of metfor ...... randomized presurgical trial.

@en

Differential effects of metfor ...... randomized presurgical trial.

@nl

P1433

Q34334262-ED97948A-CA7F-4E62-B94F-4232A0D5C5E2

P1476

Q34334262-88D003EA-1C8D-49D3-AAF5-EDB448D314AB

P2093

Q34334262-0C56360D-CEE0-4DEC-860E-D42F5E1368B3

Q34334262-153E0921-65FE-4505-9422-14289708A4DF

Q34334262-1B234739-4FA9-4D79-B503-5ECFF53AD5D8

Q34334262-24AF9DED-2014-4352-9C66-7F24B0586681

Q34334262-5B3E3EB6-0F36-452D-9217-C1CB0DC4707D

Q34334262-79B5C403-BFCF-4C4B-8A82-581219B303BA

Q34334262-AF7FAC22-A238-4A19-8FF6-B0B3592A36EF

Q34334262-C9BC4183-2B71-420E-B355-E5C774AB7A0D

Q34334262-CC8FFFB1-8673-4333-8D46-4479ABC56592

Q34334262-E938F449-D136-4767-B27A-D27E610C6438

P2860

Q34334262-106ACBD0-D102-4803-80F7-D480DC81E757

Q34334262-121435EB-2E6F-44FB-87BD-F96038C36E78

Q34334262-12E88B26-0F48-4654-802F-59AA131E1DCA

Q34334262-134C1A3B-994B-49E2-9031-22BAC009DE29

Q34334262-13D88455-1180-4624-9698-27E37AAF05E6

Q34334262-1B4EAC74-69B8-4FB6-92FE-EB9F49AAAAD1

Q34334262-1F0845CA-AC9C-4E28-9A46-DEBA5C779C8E

Q34334262-2771FE92-90C9-4637-9358-E2170C75114D

Q34334262-296E10E8-964D-4D1D-A179-F6B3610B18F9

Q34334262-2C2D14EB-F415-416F-BC2A-9FA66A189FB1

P2888

Q34334262-23EBC71B-F9F4-4F60-92C0-033C62ECDC3F

P304

Q34334262-EA693F03-885C-4B35-901A-E92FE506D66C

P31

Q34334262-776E7E96-06BE-437C-AD01-77A43608A71E

P356

Q34334262-30166735-824B-4F26-BC25-E1F882965A38

P407

Q34334262-D561F02F-51C5-45F7-9D04-668E23E30638

P433

Q34334262-4A121C0C-36F4-41C0-8B42-A4EC64198BF8

P478

Q34334262-B1D81039-56F4-4725-BDC7-A482F3DA4C71

P50

Q34334262-1716FBA6-7F1C-484A-AC68-4051081FD2C4

Q34334262-24777083-08B5-4324-A2D6-78AA696F0402

Q34334262-5202B8B4-438C-45E1-96B5-CECE29E0F089

Q34334262-7644B7D6-20E9-47B7-8A89-1C9D392160A9

Q34334262-CAEA2B49-042A-479E-8E80-87ED3A09B749

Q34334262-F7A427D5-070D-4719-AB3F-4FFBC930045A

P577

Q34334262-F24DC3D2-3CEB-4CFE-BF3C-95697023045B

P5875

Q34334262-F2599D28-E580-45FC-95FC-E870DCE2514E

P6179

Q34334262-6BA6B251-7202-4429-B5E0-230C80EC69B9

P698

Q34334262-DFC79155-08F2-4F9B-84C4-AE12F7AEDDFF

P921

Q34334262-000E6E89-21B8-4602-A1AD-2ECA3AE426EB

Q34334262-A3BC27A7-C5A4-4CFF-A908-91F5644C7723

P932

Q34334262-69C1852B-0164-4AD5-8734-98E4C6D98AE8

P356

S10549-014-3141-1

P1433

Breast Cancer Research and Treatment

P1476

Differential effects of metfor ...... a randomized presurgical trial

@en

P2093

Alberto Luini

http://www.w3.org/2001/XMLSchema#string

Andrea DeCensi

http://www.w3.org/2001/XMLSchema#string

Bernardo Bonanni

http://www.w3.org/2001/XMLSchema#string

Davide Serrano

http://www.w3.org/2001/XMLSchema#string

Fabio Bassi

http://www.w3.org/2001/XMLSchema#string

Giancarlo Pruneri

http://www.w3.org/2001/XMLSchema#string

Harriet Ann Johansson

http://www.w3.org/2001/XMLSchema#string

Massimiliano Cazzaniga

http://www.w3.org/2001/XMLSchema#string

Matthias Schwab

http://www.w3.org/2001/XMLSchema#string

Michael N Pollak

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes

Clinical Pharmacokinetics of Metformin

Contraindications to the use of metformin

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

Investigating metformin for cancer prevention and treatment: the end of the beginning

Metformin and the risk of cancer: time-related biases in observational studies

Metformin in breast cancer: time for action

Metformin increases plasma ghrelin in Type 2 diabetes.

Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy.

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders.

P2888

s10549-014-3141-1

P304

81-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-014-3141-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P50

Matteo Lazzeroni

A Guerrieri-Gonzaga

P577

2014-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266152123

http://www.w3.org/2001/XMLSchema#string

P6179

1008811529

http://www.w3.org/2001/XMLSchema#string

P698

25253174

http://www.w3.org/2001/XMLSchema#string

P921

P932

4196136

http://www.w3.org/2001/XMLSchema#string